Sakari Simula

Mikkeli, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

AI-driven MRI analysis reveals brain atrophy patterns in benign relapsing-remitting multiple sclerosis.

AI-driven MRI analysis reveals brain atrophy patterns in benign relapsing-remitting multiple sclerosis.

Journal: Frontiers in neurology

Published: February 03, 2025

Fatigue and health-related quality of life depend on the disability status and clinical course in RRMS.

Fatigue and health-related quality of life depend on the disability status and clinical course in RRMS.

Journal: Multiple sclerosis and related disorders

Published: January 05, 2023

Grey matter atrophy in patients with benign multiple sclerosis.

Grey matter atrophy in patients with benign multiple sclerosis.

Journal: Brain and behavior

Published: December 27, 2021

Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis.

Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: September 04, 2021

Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients.

Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients.

Journal: Journal of neurology

Published: February 21, 2021

Corrigendum to "Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation" [Multiple Sclerosis and Related Disorders 38 (2020) 101498].

Corrigendum to "Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation" [Multiple Sclerosis and Related Disorders 38 (2020) 101498].

Journal: Multiple sclerosis and related disorders

Published: June 24, 2020

Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation.

Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation.

Journal: Multiple sclerosis and related disorders

Published: May 09, 2019

Cardiac repolarization evolves differently during the course of benign and disabling multiple sclerosis.

Cardiac repolarization evolves differently during the course of benign and disabling multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: December 17, 2017

Cardiac repolarization during fingolimod treatment in patients with relapsing-remitting multiple sclerosis.

Cardiac repolarization during fingolimod treatment in patients with relapsing-remitting multiple sclerosis.

Journal: Brain and behavior

Published: June 09, 2017

The impact of multiple sclerosis onset symptom on cardiac repolarization.

The impact of multiple sclerosis onset symptom on cardiac repolarization.

Journal: Brain and behavior

Published: April 21, 2017

Sequence of cardiovascular autonomic alterations after fingolimod initiation.

Sequence of cardiovascular autonomic alterations after fingolimod initiation.

Journal: Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc

Published: August 26, 2016

Heart rate variability predicts the magnitude of heart rate decrease after fingolimod initiation.

Heart rate variability predicts the magnitude of heart rate decrease after fingolimod initiation.

Journal: Multiple sclerosis and related disorders

Published: July 31, 2016

Showing 1-12 of 20

Last Updated: 09/26/2026